Andreas Klosterman, Ph.D. (CSO) will give an update on selectION’s best-in-class ion channel antagonists and discuss the principles of the company’s systematical peptide design to obtain the most selective and specific ion channel blockers.
Site Search
Recent News
- Meet selectION, Inc. at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 13th-16th, 2025
- selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis
- Meet selectION, Inc. at the BIO International Convention in San Diego, CA, on June 3rd to 6th, 2024